IO Biotech, Inc.
IO Biotech, Inc. (IOBT): 31 pipeline candidates · ~5 mo cash runway · 83 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E 42.86 · 0% dilution
Lead: Phase 2
31 candidates
N/A
N/A
A transparent, data-derived signal for IO Biotech, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.5M
Cash
$30.7M
Quarterly Burn
$18.5M
Runway
5.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (31 candidates)
| Drug | Phase |
|---|---|
| ace1831 | Phase 1 |
| anti tnf therapy including infliximab | — |
| cay001 | Phase 1 |
| crotoxin | Phase 1 |
| cylembio | Phase 2 |
| dual-target antigen-selected car-nk | Phase 1/Phase 2 |
| eb-select single-target car-nk cells | Phase 1/Phase 2 |
| fludarabine | Phase 1 |
| ghk-cu gel-peptide complex) | Phase 2 |
| hb-1 | Phase 2 |
Showing 10 of 31 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in IO Biotech, Inc.'s pipeline?
IO Biotech, Inc. (IOBT) has 31 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IO Biotech, Inc.'s lead drug candidate?
IO Biotech, Inc.'s most advanced tracked candidate is ace1831 (Phase 1) for B-cell Lymphoma.
What is IO Biotech, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IO Biotech, Inc. has approximately 5.3 months of cash runway.
What is IO Biotech, Inc.'s market capitalization?
IO Biotech, Inc.'s market capitalization is approximately $3.5M.
Who is the CEO of IO Biotech, Inc.?
Dr. Mai-Britt Zocca Ph.D. is the chief executive officer of IO Biotech, Inc. (IOBT).
Get the full picture on IO Biotech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.